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Introduction
Perfluorooctane sulfonate (PFOS) has 
until recently been widely used in a variety 
of applications, especial ly in surface 
coatings used to make products water- and 
 oil- resistant. PFOS is highly biopersistent 
with a half-life in humans of about 5 years 
(Olsen et al. 2007). PFOS was added to 
Annex B of the Stockholm Convention on 
Persistent Organochlorine Pollutants in 
2009, and the production and use of PFOS 
have been regulated in Europe since 2008 
(European Commission 2006). In Norway, 
PFOS levels rose through the mid-1990s, 
and have declined since 2000 (Haug et al. 
2009). However, model-based estimates 
of future environmental PFOS exposures 
suggest a slower decay in temperate regions 
(Armitage et al. 2009). PFOS has been 
detected in human populations from all 
over the world, but considerable variation in 
exposure has been observed between popula-
tions (Lau et al. 2004). Most previous studies 
have measured PFOS in serum, and the 
highest concentrations have been observed 
among workers at facilities producing 
PFOS, with mean PFOS concentrations of 
1,000–2,000 ng/mL, whereas general popula-
tions on average had concentrations of about 
35 ng/mL PFOS around the peak exposure 
period (Lau et al. 2004). Apart from the 
present study population (Jensen et al. 2012), 
PFOS has to our knowledge been measured 
in amniotic fluid only in one recent American 
study of 28 women (Stein et al. 2012). That 
study indicated a PFOS concentration in 
amniotic fluid about 20-fold less than in 
maternal serum.
Experimental studies of the effects of 
PFOS on adult male reproductive function 
have reported reduced testosterone produc-
tion, altered gonadotropin secretion, and 
reduced epididymal sperm in PFOS-treated 
rats and mice (López-Doval et al. 2014; 
Wan et al. 2011). Studies of human adults 
have shown associations between PFOS 
exposure and the proportion of normal sperm 
cells (Joensen et al. 2009; Toft et al. 2012) 
although these results were not corroborated 
in a recent study (Joensen et al. 2013), and 
other aspects of semen quality seem to be 
unaffected (Joensen et al. 2009, 2013; Toft 
et al. 2012). Apart from an inverse association 
between PFOS exposure and testosterone 
level in one study (Joensen et al. 2013), 
no significant associations between PFOS 
exposure and reproductive hormones in adult 
men have been observed (Joensen et al. 2009; 
Raymer et al. 2012; Specht et al. 2012).
There have been fewer studies on the 
effects of PFOS exposure on fetal steroidogen-
esis, and later reproductive function. A study 
on rat fetal Leydig cell function indicated that 
20 mg/kg/day exposure of pregnant rats from 
gestational days 11 to 19 was associated with 
reduced testosterone production, reduced fetal 
Leydig cell number, and decreased expres-
sion of steroidogenic enzymes (Zhao et al. 
2014). Also, zebrafish embryos showed altered 
expression of stereoidogenic enzymes after 
exposure to up to 500 μg/L PFOS from 4 
to 120 hr past fertilization (Du et al. 2013). 
Vested et al. (2013) studied whether prenatal 
exposure to PFOS (measured in maternal 
serum) was associated with adult male repro-
ductive function among 169 Danish men 
born in 1988–1989. Although prenatal PFOS 
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Background: Exposure to perfluorooctane sulfonate (PFOS) may potentially disturb fetal Leydig 
cell hormone production and male genital development.
oBjectives: We aimed to study the associations between levels of amniotic fluid PFOS, fetal steroid 
hormone, and insulin-like factor 3 (INSL3) and the prevalence of cryptorchidism and hypospadias.
Methods: Using the Danish National Patient Registry, we selected 270 cryptorchidism cases, 
75 hypospadias cases, and 300 controls with stored maternal amniotic fluid samples available in a 
Danish pregnancy-screening biobank (1980–1996). We used mass spectrometry to measure PFOS 
in amniotic fluid from 645 persons and steroid hormones in samples from 545 persons. INSL3 
was measured by immunoassay from 475 persons. Associations between PFOS concentration in 
amniotic fluid, hormone levels, and genital malformations were assessed by confounder-adjusted 
linear and logistic regression.
results: The highest tertile of PFOS exposure (> 1.4 ng/mL) in amniotic fluid was associated with 
a 40% (95% CI: –69, –11%) lower INSL3 level and an 18% (95% CI: 7, 29%) higher testosterone 
level compared with the lowest tertile (< 0.8 ng/mL). Amniotic fluid PFOS concentration was not 
associated with cryptorchidism or hypospadias.
conclusions: Environmental PFOS exposure was associated with steroid hormone and INSL3 
concentrations in amniotic fluid, but was not associated with cryptorchidism or hypospadias in 
our study population. Additional studies are needed to determine whether associations with fetal 
hormone levels may have long-term implications for reproductive health.
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exposure was not associated with reproduc-
tive hormones or semen quality, prenatal 
exposure to perfluorooctanoate (PFOA) was 
associated with reduced semen quality and 
higher levels of luteinizing hormone (LH) 
and  follicle- stimulating hormone (FSH) in 
young adult men. These results suggest 
that the prenatal period may be sensitive to 
environmental exposures to perfluoroalkyl 
substances (PFAS).
Evidence of effects on fetal Leydig cell 
hormone production has led others to 
hypothesize that PFOS exposure might 
affect androgen- and insulin-like factor 3 
(INSL3)–dependent testicular descent (Bay 
et al. 2011) and scrotal fusion (Kalfa et al. 
2009). Only one previous study has evalu-
ated the risk of cryptorchidism in relation to 
PFAS exposure; this study did not observe 
associations between PFAS level in cord 
blood and cryptorchidism (Vesterholm et al. 
2014). However, due to a limited study size 
of 59 cryptorchidism cases and 108 matched 
controls, the power to show an association 
was limited. To our knowledge, no previous 
studies have evaluated the potential associa-
tion between in utero exposure to PFOS and 
fetal hormone level or hypospadias.
The aim of the present study was to 
determine whether in utero PFOS levels are 
associated with altered Leydig cell function, 
as indicated by steroid hormone and INSL3 
concentrations in amniotic fluid, and to 
evaluate whether these potential effects on 
hormone levels were associated with genital 
malformation in offspring.
Methods
Study population and amniotic fluid samples. 
The study population has been described 
previously in detail (Jensen et al. 2012). 
Briefly, we used amniotic fluid samples from 
a Danish biobank maintained at the State 
Serum Institute in Copenhagen (http://www.
ssi.dk). The biobank holds samples from a 
pregnancy-screening registry, including 
information on amniotic fluid samples from 
63,882 pregnancies covering the period 
1980–1996. After restriction to live-born 
singleton boys with complete obstetric data, 
25,105 pregnancies were eligible (Jensen 
et al. 2012). The amniotic fluid samples 
were centrifuged before routine diagnostic 
analyses, and the supernatants were kept 
frozen at –20°C until the present analyses 
were carried out. Indications for amniocen-
tesis included age ≥ 35 years and/or increased 
risk of severe malformations or Down 
syndrome based on results from maternal 
serum analyses. We calculated the gestational 
week of amniocentesis based on the date of 
amniocentesis, the date of birth, and the esti-
mated gestational age at birth as described 
by Jensen et al. (2012). Each sample in the 
pregnancy-screening registry was recorded by 
the personal identification number (unique to 
each Danish citizen) of the pregnant woman. 
We used these unique identifiers to obtain 
obstetric data on the pregnancies from the 
Danish Medical Birth Registry (Knudsen 
and Olsen 1998), including gestational age 
at birth, singleton or multiple birth, maternal 
parity, and birth weight and Apgar score of 
the infant. In addition, we used the unique 
identifiers in the Danish Civil Registration 
System to identify male offspring from the 
pregnancies (Pedersen et al. 2006).
The Danish Regional Ethics Committee, 
the Danish National Board of Health, and 
the Danish Data Protection Agency approved 
the study. The use of the biobank for research 
purposes has been approved, and additional 
informed consent from the study subjects for 
this specific project was neither recommended 
nor required.
Case–control definitions and ascertain-
ment. Controls were randomly selected from 
the 25,105 amniotic fluid samples belonging 
to live-born male offspring pregnancies in the 
screening database with complete obstetric 
data in the Danish Medical Birth Registry. 
The number of controls (n = 412) was chosen 
to roughly equal the largest case group 
consisting of 404 boys with cryptorchidism. 
Cryptorchidism cases had both a diagnosis 
of undescended testis according to the 
International Classification of Diseases, 8th and 
10th Revisions [ICD-8: 75210, 75211, 75219; 
ICD-10: Q53, Q531(A), Q532(A), Q539] 
and a corrective surgical procedure according 
to the Surgery and Treatment Classification 
of the Danish National Board of Health 
(STC: 55600, 55640) or the Nordic 
Classification of Surgical Procedures (NCSP: 
KKFH00, KKFH01, KKFH10) recorded 
in the Danish National Patient Registry 
(DNPR). Boys with a registry entry of 
inguinal hernia repair (STC: 40620, 40640; 
NCSP: KJAB00-KJAB97) were excluded 
from this case group to avoid iatrogenic 
cryptorchidism secondary to hernia repair. 
We included all boys that fulfilled these 
criteria (404 of 25,105; 1.61%) to maximize 
the cryptorchidism case group and overall 
study size. For the hypospadias case group we 
included all 109 of the 25,105 boys (0.43%) 
with a diagnosis of hypospadias in the DNPR 
(ICD-8: 75220, 75221, 75222, 75228, 
75229; ICD-10: Q540, Q541, Q542, Q548, 
Q549). All boys were followed for the afore-
mentioned diagnoses and surgery entries in 
the DNPR from birth until November 2008.
Measurement of chemical compounds 
and hormones. During all chemical analyses, 
laboratory technicians were blinded to 
case–control status and to levels of analytes 
measured by others. We assayed PFOS and 
cotinine in amniotic fluid as described in 
detail by Jensen et al. (2012). Coefficients of 
variation were 11% for PFOS and 9% for 
cotinine; the limit of detection (LOD) was 
0.20 ng/mL for PFOS and cotinine, deter-
mined as the concentrations corresponding 
to three times the standard deviation of the 
responses in chemical blanks. We analyzed 
the samples using a liquid chromatograph 
(LC; model UFLCXR, Shimadzu Corp). The 
LC was connected to a hybrid triple quadru-
pole linear ion trap tandem mass spectrom-
eter (LC/MS/MS) equipped with a turbo ion 
spray source (QTRAP 5500; AB Sciex).
We assayed the steroid hormones 
testosterone, androstenedione, proges-
terone, 17-OH-progesterone, and cortisol 
in amniotic fluid at the Danish Center for 
Neonatal Screening, Department of Clinical 
Biochemistry and Immunology, the State 
Serum Institute, Copenhagen, Denmark. The 
online extraction LC-MS system consisted 
of an Aria TLX2 system (Thermo Scientific) 
with two Agilent 1100 binary pumps and 
two Agilent 1200 quaternary pumps (Agilent) 
connected to a Thermo TSQ Ultra triple quad-
rupole mass spectrometer equipped with an 
APCI ion source. Extraction was performed 
using a Cyclone P 0.5 × 50 mm Turboflow 
column (Thermo Scientific), and analytical 
separation was achieved using Kinetix 2.6 μ 
2.1 × 50 mm C18 columns (Phenomenex). 
All calibrators, controls, internal standards, 
and micro-titer plates were purchased from 
PerkinElmer via their CHS steroid profiling kit 
for mass spectrometry (PerkinElmer). Formic 
acid was purchased from Merck. Ammonium 
acetate and zinc sulphate heptahydrate 
were purchased from Sigma-Aldrich. Water 
was purified using a water purification unit 
from Millipore. We used a volume of 50 μL 
amniotic fluid for the assay. The LODs and 
the intra- and interassay coefficients of varia-
tion were as follows: testosterone, 0.1 nmol/L, 
9 and 10%, respectively; androstenedione, 
0.3 nmol/L, 8 and 9%, respectively; proges-
terone, 0.4 nmol/L, 10 and 11%, respectively; 
17-OH-progesterone, 0.4 nmol/L, 9 and 10%, 
respectively; and cortisol, 4.4 nmol/L, 10 and 
12%, respectively.
INSL3 in amniotic fluid was measured 
using a semicompetitive time-resolved fluo-
rometric immunoassay (TRFIA) slightly 
modified from that described in detail by 
Anand-Ivell et al. (2006). The laboratory work 
was performed at Leibniz Institute for Farm 
Animal Biology, Dummerstorf, Germany. 
The modifications involved the replacement 
of the original rat antiserum by a new poly-
clonal antiserum (no. #RIA5) raised in rabbits 
(IMVS Antibody Services) against the same 
chemically synthesized human INSL3 as 
previously, at a final dilution of 1:10,000. As 
tracer, we used the same Europium-labeled 
human INSL3 as described (Anand-Ivell 
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et al. 2006). Accordingly, also the secondary 
goat-anti-rabbit  antibody (Rockland 
Immunochemicals Inc.) used to coat the plates 
substituted for the original anti-rat antibody. 
All other conditions were similar. Standard 
curves for measurement of amniotic fluid were 
constructed using serial dilutions of human 
INSL3 in EDTA–phosphate-buffered saline 
(Anand-Ivell et al. 2008). A volume of 100 μL 
amniotic fluid was used for the assay, and 
the limit of detection for the modified assay 
was 0.01 ng/mL, with inter- and intraplate 
coefficients of variation of < 8% and < 1%, 
respectively, across the range. There was no 
cross-reactivity detectable across the physi-
ological range with the structurally related 
peptides, insulin, IGF-1 (insulin-like growth 
factor-1), and relaxin. There was also no 
cross-reactivity detectable with rat INSL3, 
and only 10% cross-reactivity with bovine 
INSL3 at the highest values. Spiking experi-
ments into normal male and female human 
sera from previous studies (Anand-Ivell et al. 
2006, 2013) indicated 122.9 + 1.5% and 
96.5 + 2.7% recovery, respectively. INSL3 
measurements of human serum following 
five successive freeze–thaw cycles showed no 
significant change (data not shown).
Statistical analysis. We imputed values 
below the LOD of our chemical assays with a 
random value between the LOD and LOD/2 
as a simplified method of maintaining vari-
ability in values below LOD. For the INSL3 
assay, 58 of 543 (10.7%) samples were below 
the LOD (0.01 ng/mL). For the PFOS assay, 
10 of 645 (1.6%) samples were below the 
LOD (0.2 ng/mL). For the steroid assay 
(n = 574), we used the instrument readout 
for values below the LOD; two (0.3%) testos-
terone values < 0.1 nmol/L, no androstene-
dione values < 0.3 nmol/L, no progesterone 
values < 0.4 nmol/L, no 17-OH-progesterone 
values < 0.4 nmol/L, and six (1.0%) cortisol 
values < 4.4 nmol/L.
INSL3 levels are highly dependent on 
gestational age at amniocentesis with a peak 
around week 15 (Anand-Ivell et al. 2008). 
We calculated multiple of the median 
(MoM) values for INSL3 by gestational age 
at amniocentesis to reduce this dependence 
(Knight and Palomaki 2003). We used the 
random sample control group to estimate the 
median level for each week, and all INSL3 
values (cases and controls) were then divided 
by the median of the corresponding week to 
calculate the MoM value. Weeks 11–13 were 
pooled because of limited number of observa-
tions, and the median value from week 21 
(controls) was applied to week 22 (cases) 
because there were no controls in week 22. 
All statistical analyses were presented for both 
the raw and the MoM INSL3 measures.
Associations between PFOS exposure 
and the included outcomes were evaluated by 
multiple linear or logistic regression analyses 
for continuous and categorical outcomes, 
respectively. We divided PFOS exposure into 
tertiles to quantify the difference between the 
highest and lowest third of the population 
and to evaluate whether any marked devia-
tions from a linear association was evident.
Differences in median hormone level 
between the PFOS tertiles were evaluated 
by the nonparametric Kruskal–Wallis test. 
Then adjusted linear regression analyses were 
performed evaluating tertile differences. We 
additionally performed regression analyses 
on a continuous PFOS variable to test for a 
linear trend.
Data are presented as difference from the 
lowest tertile and β [95% confidence interval 
(CI)] for linear regression models both unad-
justed and adjusted. We performed inter-
action analyses including a ln-PFOS × case/
control group term in the regression models 
to evaluate whether combined analyses of 
cases of cryptorchidism, hypospadias, and 
control groups were statistically justifiable. 
In supplementary analyses, we additionally 
evaluated the association between PFOS and 
hormones separately for controls, cryptorchi-
dism cases, and hypospadias cases to evaluate 
whether the association varied across groups. 
We a priori decided to adjust all hormone 
analyses for gestational age of amniocentesis 
(continuous, weeks), maternal age (years), and 
smoking (using amniotic fluid specific levels 
as a biomarker for nonsmoker: < 25 ng/mL 
cotinine; passive smoker: 25–85 ng/mL; and 
smoker: > 85 ng/mL) (Jauniaux et al. 1999). 
Analysis of combined associations between 
PFOS and hormone levels across case and 
control groups were additionally adjusted for 
case–control status. The logistic regression 
analyses of cryptorchidism and hypospadias 
was adjusted for gestational age of amnio-
centesis (continuous, weeks), year of amnio-
centesis (three groups), maternal age (years), 
gestational age (weeks), birth weight (grams), 
and smoking (cotinine groups). To further 
evaluate whether year of amniocentesis influ-
enced these associations, we made supplemen-
tary stratified analysis by year of amniocentesis 
(1980–1986, 1987–1992, and 1992–1996).
We also restricted the analyses to boys 
with no other congenital malformations to 
exclude cases with syndromes and chromo-
somal abnormalities.
PFOS and all hormone data were trans-
formed by the natural logarithm (ln) to 
improve normality of their distribution of 
residuals in the regression analyses.
Results
Of the original 925 included subjects in the 
cohort, we could not locate samples in the 
biobank for 60 subjects, and 220 had insuf-
ficient volume for PFOS measurements. 
Thus, the study population consists of 645 
mother–child pairs with information on 
fetal PFOS exposure and case status of the 
children, including 270 cases of cryptorchi-
dism, 75 cases of hypospadias, and a random 
control group of 300. The mean and standard 
deviation of maternal characteristics including 
age and gestational age of amniocentesis and 
distribution of smoking prevalence did not 
differ markedly between the case and control 
groups (Table 1). As expected, the cryptor-
chidism and hypospadias cases weighed less 
and were on average born slightly earlier 
than the control group. Also, the distribu-
tion of calendar year of amniocentesis differed 
between case groups (Table 1).
Amniotic fluid steroid hormone levels were 
measured on 545 pregnant women with suffi-
cient sample volume (84% of cryptorchidism 
cases, 100% of hypospadias cases, and 81% 
of control samples). Testosterone level was 
positively associated with PFOS exposure with 
18% higher testosterone (95% CI: 7, 29%) 
in the highest PFOS tertile compared with 
the lowest in the overall population (all three 
groups combined). Also, the linear trend test 
showed a significant positive association in both 
the unadjusted and adjusted analysis (Table 2).
Table 1. Characteristics of the included pregnancies and boys by case–control status among Danish 
pregnant women with amniocentesis (1980–1996).
Characteristics
Control  
(n = 300)
Cryptorchidism  
(n = 270)
Hypospadias 
(n = 75)
Maternal age at birth [years (mean ± SD)] 32.6 ± 5.3 32.8 ± 5.3 31.3 ± 5.8
Gestational week of amniocentesis (mean ± SD) 15.7 ± 1.3 15.9 ± 1.8 15.6 ± 1.6
Gestational age at birth [weeks (mean ± SD)] 39.6 ± 1.5 39.2 ± 2.2 38.7 ± 2.8
Birth weight [g (mean ± SD)] 3,535 ± 561 3,370 ± 682 3,216 ± 827
Year of amniocentesis (%)
1980–1984 34 40 17
1985–1990 34 32 37
1991–1996 33 29 45
Smoking (%) 
Nonsmoker: cotinine < 25 ng/mL 61 60 58
Passive smoker: cotinine 25–85 ng/mL 6 4 7
Smoker: cotinine ≥ 85 ng/mL 33 36 35
Congentital malformations (%)a 6 14 20
aMalformations other than cryptorchidism and hypospadias.
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Also, androstendione, progesterone, 
17-OH-progesterone, and cortisol, but not 
DHEAS (dehydroepiandrosterone sulfate), 
were positively associated with PFOS exposure 
(Table 2). INSL3 was measured in amniotic 
fluid samples from 475 pregnancies (74% 
of cryptorchidism cases, 84% of hypospa-
dias cases, and 71% of controls). INSL3 
was negatively associated with PFOS, with a 
40% lower INSL3 concentration (95% CI: 
–69, –11%) estimated for the highest tertile 
compared with the lowest based on the overall 
adjusted model, and approximately the same 
magnitude when evaluated as INSL3 MoM. 
The inverse associations were confirmed by 
linear trend analyses (Table 2).
The association between PFOS exposure, 
testosterone, and INSL3 was similar in the 
case and control groups as indicated by 
p-values of product interaction terms in the 
regression models (Table 2) and estimates 
(Table 3). However, in the stratified analysis, 
fewer statistical significant associations were 
observed, probably because of a lower number 
of cases (Table 3).
PFOS concentrations in amniotic fluid 
were not associated with cryptorchidism 
or hypospadias based on adjusted logistic 
regression models (Table 4). Supplementary 
analysis stratifying these associations by 
sampling year (1980–1986, 1987–1992, 
and 1992–1996) also did not indicate any 
association between PFOS exposure and 
odds for cryptorchidism or hypospadias 
(data not shown). Furthermore, analyses 
restricted to boys with no other congenital 
malformations (numbers given in Table 1) 
produced  essentially unchanged results (data 
not shown).
Discussion
PFOS concentrations measured in amniotic 
fluid were associated with higher steroid 
hormone levels and lower INSL3 in the 
combined study population but were not asso-
ciated with cryptorchidism or hypospadias 
(270 and 75 cases, respectively, compared 
with 300 controls).
Our results are consistent with those of 
Vesterholm et al. (2014), who reported no 
association of cord blood concentrations of 
PFOS or other PFAS with cryptochidism in 
215 Danish and Finnish boys.
To our knowledge, the present study is the 
first human study evaluating potential asso-
ciation between fetal exposure to PFOS and 
biomarkers of human fetal steroid and INSL3 
levels. A study using the human adrenocor-
tical carcinoma (H295R) in vitro cell assay 
reported increased testosterone, progesterone, 
and estradiol secretion after PFOS exposure 
(Kraugerud et al. 2011), supporting the 
possibility that prenatal PFOS exposure may 
increase fetal steroid hormone production.
The inverse association between prenatal 
concentrations of PFOS and INSL3 may be 
consistent with a direct effect on fetal Leydig 
cells, because, based on the current knowl-
edge, INSL3 is produced only by male fetal 
Leydig cells, whereas steroid hormones are 
also produced by the fetal adrenal gland 
(Anand-Ivell and Ivell 2014). Fetal urine is 
believed to be the primary source of steroid 
hormones in amniotic fluid from the second 
trimester onward (Schindler 1982). The 
source or sources of steroids in the amniotic 
fluid are unknown, but could include the 
umbilical cord or placenta (Schindler 1982). 
Progesterone and estradiol are produced 
in considerable amounts in the placenta, 
and may be partly transferred to the fetus 
(Pasqualini 2005). A recent in vitro study 
using human placental cells indicated that 
placental aromatase activity may be altered 
after exposure to PFOS (Gorrochategui et al. 
2014). Thus, higher testosterone levels in 
amniotic fluid in our study population might 
be attributable to inhibited aromatase activity 
in the placenta. However, whereas andros-
tendione and DHEAS concentrations were 
weakly correlated between second-trimester 
amniotic fluid and maternal serum samples 
from mothers expecting male offspring, 
Table 2. PFOS exposure (ng/mL) and markers of Leydig cell function in amniotic fluid among Danish pregnant women with amniocentesis (1980–1996).
aAdjusted for gestational age of amniocentesis, maternal age, smoking (cotinine groups), and case or control status unless otherwise indicated. bKruskal–Wallis rank test. cEstimates 
represent the percent difference in hormone concentrations with a 1% increase in PFOS. dInteraction terms (lnPFOS × case–control status) in adjusted linear regression models. 
eMultiple of the median (MoM) values are calculated as specified in the methods.
Hormone and PFOS exposure n Median hormone level % difference (95% CI)a
Testosterone (nmol/L) 545
< 0.8 ng/mL PFOS 0.73 Reference
0.8–1.4 ng/mL PFOS 0.81 9 (–2, 20)
> 1.4 ng/mL PFOS 0.91 18 (7, 29)
p-Valueb 0.002
Ln-PFOS (crude)c 0.14 (0.08, 0.22)
Ln-PFOS (adjusted)c 0.16 (0.09, 0.23)
p-Value for interactiond 0.68
DHEAS (nmol/L) 545
< 0.8 ng/mL PFOS 17.0 Reference
0.8–1.4 ng/mL PFOS 17.4 5 (–10, 20)
> 1.4 ng/mL PFOS 17.4 2 (–14, 17)
p-Valueb 0.93
Ln-PFOS (crude)c 0.06 (–0.03, 0.16)
Ln-PFOS (adjusted)c 0.07 (–0.03, 0.16)
p-Value for interactiond 0.03
Androstendione (nmol/L) 545
< 0.8 ng/mL PFOS 2.62 Reference
0.8–1.4 ng/mL PFOS 2.72 8 (0, 17)
> 1.4 ng/mL PFOS 3.07 17 (8, 25)
p-Valueb 0.001
Ln-PFOS (crude)c 0.15 (0.10, 0.20)
Ln-PFOS (adjusted)c 0.15 (0.10, 0.21)
p-Value for interactiond 0.22
Progesterone (nmol/L) 545
< 0.8 ng/mL PFOS 163.7 Reference
0.8–1.4 ng/mL PFOS 170.8 11 (0, 23)
> 1.4 ng/mL PFOS 186.4 22 (11, 34)
p-Valueb 0.001
Ln-PFOS (crude)c 0.21 (0.14, 0.28)
Ln-PFOS (adjusted)c 0.21 (0.14, 0.29)
p-Value for interactiond 0.07
Hormone and PFOS exposure n Median hormone level % difference (95% CI)a
17-OH-Progesterone (nmol/L) 545
< 0.8 ng/mL PFOS 4.94 Reference
0.8–1.4 ng/mL PFOS 5.22 7 (–1, 13)
> 1.4 ng/mL PFOS 6.18 18 (11, 26)
p-Valueb < 0.001
Ln-PFOS (crude)c 0.17 (0.12, 0.22)
Ln-PFOS (adjusted)c 0.15 (0.11, 0.20)
p-Value for interactiond 0.92
Cortisol (nmol/L) 545
< 0.8 ng/mL PFOS 15.9 Reference
0.8–1.4 ng/mL PFOS 17.0 9 (–0, 17)
> 1.4 ng/mL PFOS 22.4 28 (19, 37)
p-Valueb < 0.001
Ln-PFOS (crude)c 0.26 (0.20, 0.32)
Ln-PFOS (adjusted)c 0.19 (0.13, 0.25)
p-Value for interactiond 0.96
INSL3 (ng/mL) 475
< 0.8 ng/mL PFOS 0.14 Reference
0.8–1.4 ng/mL PFOS 0.12 –21 (–48, 7)
> 1.4 ng/mL PFOS 0.09 –40 (–69,–11)
p-Valueb < 0.001
Ln-PFOS (crude)c –0.35 (–0.54, –0.16)
Ln-PFOS (adjusted)c –0.21 (–0.40, –0.02)
p-Value for interactiond 0.98
INSL3 (MoM)e 475
< 0.8 ng/mL PFOS 1.45 Reference
0.8–1.4 ng/mL PFOS 1.13 –21(–49, 8)
> 1.4 ng/mL PFOS 0.85 –39 (–68,–10)
p-Valueb 0.07
Ln-PFOS (crude)c –0.17 (–0.36, 0.01)
Ln-PFOS (adjusted)c –0.20 (–0.38, –0.01)
p-Value for interactiond 0.82
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testosterone concentrations were not corre-
lated, suggesting limited maternal to fetal 
transfer of testosterone relative to other steroid 
hormones (van de Beek et al. 2004).
In utero exposure of rats to di(n-butyl) 
phthalate, a compound with antiandrogenic 
properties, caused reduced INSL3 expression 
in fetal Leydig cells and an increase in cryptor-
chidism, and INSL3 has been suggested as an 
endogenous marker of endocrine disruption 
(Anand-Ivell and Ivell 2014). A recent study 
from our group using the same study popula-
tion as in the present study indicated that di(2-
ethylhexyl) phthalate (DEHP) metabolites but 
not diisononyl phthalate (DiNP) metabolites 
were also related to decreased INSL3 level 
(Jensen et al. 2015). However, regarding 
PFOS exposure, a recent study indicated that 
fetal rat Leydig cell INSL3 production was 
unaltered after exposure to 20 mg/kg/day 
PFOS from gestational day 11 to 19 (Zhao 
et al. 2014). There may be species differences 
in effects of PFOS on INSL3 production, 
partly because of the much shorter half-life 
of PFOS in rats than in humans (Lau et al. 
2004). In our study population, prenatal 
PFOS exposure was associated with lower 
INSL3 in amniotic fluid, but was not asso-
ciated with cryptorchidism. Whether lower 
INSL3 levels can be associated with long-term 
effects on male reproductive health is not 
known. However, it is of interest to note that 
a recent follow-up study found lower sperm 
counts and increased LH and FSH levels 
in 19- to 21-year-old males at the highest 
tertile of PFOA exposure in utero compared 
with the lowest (Vested et al. 2013). In that 
study, PFOA and PFOS was estimated from 
maternal pregnancy serum samples. Although 
no association with PFOS was found in the 
Vested et al. (2013) study, PFOS and PFOA 
were strongly correlated in maternal serum 
samples (r = 0.73). We did not measure 
PFOA in the present study; thus it cannot be 
excluded that the associations with INSL3 
may be related to an effect of PFOA rather 
than PFOS on INSL3. Future studies should 
evaluate whether low fetal INSL3 level is asso-
ciated with long-term consequences for male 
 reproductive health.
We measured PFOS, steroid hormones, 
and INSL3 in amniotic fluid for several 
reasons. Most amniotic fluid samples were 
taken in gestational weeks 15 to 17, close to 
the time window of male genital development 
in gestational weeks 8 to 15 (Scott et al. 2009). 
Contaminant concentrations in amniotic fluid 
during the first half of pregnancy, when the 
amniotic fluid is composed largely of exudates 
from fetal blood and fluids, are consid-
ered a suitable proxy measure of intrafetal 
 contaminant levels (Beall et al. 2007).
Other studies on fetal PFOS exposures 
have used maternal serum or cord blood 
as a proxy for fetal exposure (Vested et al. 
2013; Vesterholm et al. 2014). Although the 
presence in cord blood indicates that PFOS 
is transferred across the placenta to the fetus 
(Vesterholm et al. 2014), little is known 
about actual exposure level of the fetus, and 
we propose that measurement in amniotic 
fluid is the closest we can get to actual 
measurement of fetal exposure at the relevant 
time window of exposure (Jensen et al. 2012).
The strengths of the present study include 
the use of a large biobank of amniotic fluid 
samples linked with medical birth registries 
to produce a nested case–control sample 
of cryptorchidism and hypospadias cases 
selected purely based on clinical diagnoses 
that are unlikely to be related to the exposure. 
Although it might be speculated that socio-
occupational class could be related to PFOS 
exposure and detection rate of cryptorchi-
dism and hypospadias, we have previously 
shown that among Danish boys the time to 
detection of cryptorchidism is unrelated to 
socio-occupational class (Hougaard et al. 
2014). However, our register-based ascertain-
ment of cryptorchidism and hypospadias did 
not include milder forms of these outcomes 
that may spontaneously disappear during 
the first years of life, so we cannot exclude 
that PFOS exposure may be related to milder 
forms of genital malformations.
PFOS and hormone concentrations were 
measured concurrently in amniotic fluid 
samples, so we cannot confirm the temporal 
relation between PFOS exposure and 
the outcomes.
The analysis of associations between PFOS 
and hormone levels in the combined case and 
control groups may have produced biased 
estimates of associations in the source popula-
tion, if associations in the case groups differed 
from the population as a whole. Our strati-
fied and interaction analyses did not indicate 
major differences among the case and control 
groups, though sample sizes were small and 
estimates were imprecise, particularly for the 
Table 3. PFOS exposure (ng/mL) and markers of Leydig cell function in amniotic fluid among Danish 
pregnant women with amniocentesis (1980–1996) stratified by case–control group.
Hormone and PFOS exposure
Controls Cryptorchism Hypospadias
n
% difference  
(95% CI)a n
% difference  
(95% CI)a n
% difference  
(95% CI)a
Testosterone (nmol/L) 242 228 75
< 0.8 ng/mL PFOS Reference Reference Reference
0.8–1.4 ng/mL PFOS 10 (–5, 24) 14 (–4, 32) –12 (–47, 24)
> 1.4 ng/mL PFOS 19 (4, 33) 20 (3, 38) –6 (–47, 36)
Ln-PFOS (crude)b 0.12 (0.03, 0.21) 0.18 (0.08, 0.28) 0.13 (–0.11, 0.37)
Ln-PFOS (adjusted)b 0.14 (0.04, 0.23) 0.20 (0.09, 0.31) 0.00 (–0.28, 0.28)
INSL3 213 199 63
< 0.8 ng/mL PFOS Reference Reference Reference
0.8–1.4 ng/mL PFOS –28 (–72, 16) –5 (–47, 38) –49 (–118, 20)
> 1.4 ng/mL PFOS –37 (–81, 8) –38 (–82, 6) –21 (–110, 69)
Ln-PFOS (crude)b –0.26 (–0.54, 0.02) –0.39 (–0.68, –0.11) –0.62 (–1.23, 0.00)
Ln-PFOS (adjusted)b –0.22 (–0.51, 0.06) –0.20 (–0.48, 0.07) 0.02 (–0.60, 0.64)
INSL3 MoMc 213 199 63
< 0.8 ng/mL PFOS Reference Reference Reference
0.8–1.4 ng/mL PFOS –30 (–73,12) 0 (–44, 45) –60 (–135, 15)
> 1.4 ng/mL PFOS –43 (–86, –0) –30 (–75, 15) –20 (–117, 77)
Ln-PFOS (crude)b –0.24 (–0.51, 0.03) –0.09 (–0.37, 0.18) –0.28 (–0.87, 0.30)
Ln-PFOS (adjusted)b –0.27 (0.54, 0.00) –0.12 (–0.40, 0.17) –0.01 (–0.68, 0.65)
aAdjusted for gestational age of amniocentesis, maternal age, smoking (cotinine groups), and case or control status 
unless otherwise indicated. bEstimates represent the percent difference in hormone concentrations with a 1% increase 
in PFOS. cMultiple of the median (MoM) values are calculated as specified in the methods.
Table 4. Odds ratios (95% CI) for cryptorchidism or hypospadias in relation to amniotic fluid PFOS 
concentration among Danish pregnant women with amniocentesis (1980–1996).
Malformation
n 
control
n 
cases
Unadjusted 
OR (95% CI) 
Adjusted 
OR (95% CI)a
Cryptorchidism
1st tertile 102 86 1.0 (reference) 1.0 (reference)
2nd tertile PFOS 101 91 1.11 (0.74, 1.67) 1.08 (0.71, 1.63)
3rd tertile PFOS 97 93 1.09 (0.73, 1.63) 1.01 (0.66, 1.53)
Ln-PFOS 300 270 1.05 (0.81, 1.35) 0.99 (0.75, 1.30)
Hypospadias
1st tertile 102 27 1.0 (reference) 1.0 (reference)
2nd tertile PFOS 101 26 1.01 (0.55, 1.81) 0.97 (0.51, 1.87)
3rd tertile PFOS 97 22 0.82 (0.44, 1.54) 0.69 (0.35, 1.38)
Ln-PFOS 300 75 0.97 (0.65, 1.44) 0.87 (0.57, 1.34)
aAdjusted for gestational age of amniocentesis, year of amniocentesis (groups), maternal age, gestational age, birth 
weight, and smoking (cotinine groups).
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hypospadias group. However, estimates based 
only on the controls, who should be represen-
tative of the overall population, were similar to 
the estimates based on the combined case and 
control groups (Table 3).
One may speculate that evaporation 
from stored samples or differential decay may 
explain some of the associations between 
hormone level and PFOS in amniotic fluid 
samples. However, PFOS, testosterone, and 
INSL3 levels were only weakly correlated with 
year of amniocentesis (r-values of 0.07, –0.06, 
and –0.05, respectively) and the estimated 
volume left in the biobank (r-values of 0.06, 
–0.06, and –0.02, respectively), suggesting 
that any influence of storage on the observed 
results would have been minor.
The concentration of PFOS in amniotic 
fluid samples in the present sample was 
somewhat higher than a previous U.S. study of 
pregnant women from New York, 2005–2008, 
where a median of 0.4 ng/mL PFOS was 
measured in amniotic fluid (Stein et al. 2012) 
compared with 1.1 ng/mL PFOS in the present 
study. This discrepancy probably stems from 
the phaseout of PFOS in the early 2000s, after 
our sample collection (1980–1996). Because 
of the higher concentration, we were therefore 
also able to detect PFOS in 98% of our samples 
compared with 32% in the recent U.S. study 
(Stein et al. 2012) despite a similar limit of 
detection and methodology used.
Conclusions
Associations of PFOS with INSL3 and steroid 
hormone concentrations in amnionic fluid 
suggest that prenatal PFOS exposure may have 
affected fetal Leydig cell function in our study 
population. However, prenatal PFOS concen-
trations were not associated with cryptorchi-
dism or hypospadias. Additional studies are 
needed to confirm associations between PFOS 
and fetal INSL3 and steroid hormone levels, 
evaluate potential mechanisms, and determine 
whether the estimated differences in fetal 
hormone levels are associated with long-term 
consequences for male reproductive health.
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